Innate Pharma encouraging initial results for IPH4102

Thursday, Oct 27, 2016

Innate Pharma Sa Preliminary data from dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with sezary syndrome.

IPH4102 shows good safety profile.

Encouraging signs of clinical activity, with complete responses seen in skin and blood.


Source :

Other News